We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 25, 2019

Outpatient Rituximab, Ifosfamide, Etoposide in DLBCL Patients >60 Years Who Are Not Candidates for HSCT

Leukemia and Lymphoma

 

Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia and Lymphoma
Outpatient Rituximab, Ifosfamide, Etoposide (R-IE) in Patients Older Than 60 Years With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Not Candidates for Stem Cell Transplantation
Leukemia and Lymphoma 2019 Sep 12;[EPub Ahead of Print], M Joshi, J Taper, C Forsyth, P Rowlings, P Campbell, P Crispin, M Harvey, C Underhill, A Bayley, K Byth, G Huang, M Hertzberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading